Login to Your Account

Clinic Roundup

Tuesday, July 30, 2013
• Entremed Inc., of Rockville, Md., said it started a crossover bioavailability and food effect study of ENMD-2076, an oral Aurora A/angiogenic kinase inhibitor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription